Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumors |
|
Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer |
|
An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland, and the United Kingdom. |
|
The effect of baseline morphology and its change during treatment on the accuracy of Response Evaluation Criteria in Solid Tumours in assessment of liver metastases. |
|
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial |
|
Establishment of a mouse gastrointestinal stromal tumour model and evaluation of response to imatinib by small animal positron emission tomography |
|
Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors |
|
Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors |
|
Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues |
|
The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors |
|
The HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor models |
|
Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial |
|
The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters |
|
Impact of tumor chronology and tumor biology on lymph node metastasis in breast cancer |
|
In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. |
|
Inter-telomeric recombination is present in telomerase-positive human cells |
|
International expert opinion on patient-tailored management of soft tissue sarcomas |
|
Intestinal neurofibromatosis is a subtype of familial GIST and results from a dominant activating mutation in PDGFRA. |
|
Intrinsic cell memory reinforces myogenic commitment of pericyte-derived iPSCs |
|
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion |
|
Lichtmikroskopische und DNS-flowzytometrische Erfassung einer zirkadianen Variabilität der Proliferationskinetik von Ehrlich-Ascites-Tumor in vivo unter den Bedingungen tageszeitlicher Nahrungsrestriktion |
|
Metastatic HER-2-positive salivary gland carcinoma treated with trastuzumab and a taxane: a series of six patients. |
|
Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features |
|
Mitotic checkpoints and chromosome instability are strong predictors of clinical outcome in gastrointestinal stromal tumors. |
|
The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors |
|
Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. |
|
The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I. |
|
MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema |
|
Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience. |
|
The Novel HSP90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations |
|
Orale Fluoropyrimidine und neue oral bioverfügbare Modulatoren der Fluoropyrimidinwirkung |
|
Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. |
|
Patient preference for oral chemotherapy |
|
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factors. |
|
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib |
|
Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models |
|
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial |
|
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. |
|
Phase I study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor in patients with refractory solid tumors |
|
Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity |
|
A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer |
|
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours |
|
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma |
|
Phase II study of biweekly plitidepsin as second-line therapy for advanced or metastatic transitional cell carcinoma of the urothelium |
|
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens |
|
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology |
|
A possible role for microRNA-141 down-regulation in sunitinib resistant metastatic clear cell renal cell carcinoma through induction of epithelial-to-mesenchymal transition and hypoxia resistance |
|
The preclinical and clinical activity of aviscumine: a potential anticancer drug |
|
Prognostic factors in adolescents and young adults (AYA) with high risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62771 and 6 |
|
Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis. |
|
Proteolytic Processing of ErbB4 in Breast Cancer |
|
Recurrent low- to intermediate-grade chondrosarcoma of the thumb with lung metastases: an objective response to trofosfamide. |
|
Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial |
|
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial |
|
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis. |
|
Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction? |
|
Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy. |
|
Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease |
|
Sphincter sparing resection of a large obstructive distal rectal gastrointestinal stromal tumour after neoadjuvant therapy with imatinib (Glivec). |
|
Targeted therapies in the treatment of GIST: Adverse events and maximising the benefits of sunitinib through proactive therapy management |
|
Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models |
|
Thrombopoietin serum levels are elevated in patients with hepatitis B/C infection compared to other causes of chronic liver disease |
|
Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma |
|
Tumor cell-based vaccination in renal cell carcinoma: rationale. approaches, and recent clinical development |
|
Tumor genotype is an independent prognostic factor in primary gastrointestinal stromal tumors of gastric origin: a european multicenter analysis based on ConticaGIST. |
|
Tumor volume as an alternative response measurement for imatinib treated GIST patients |
|
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 |
|
Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors |
|
Using pharmacokinetic and pharmacodynamic data in early decision making regarding drug development: a phase I clinical trial evaluating tyrosine kinase inhibitor, AEE788. |
|
Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic clear-cell renal cell carcinoma patients treated with sunitinib |
|
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer |
|